DXCM Jan 2025 150.000 call
| Previous Close | 4.86 |
| Open | 5.00 |
| Bid | 4.80 |
| Ask | 5.00 |
| Strike | 150.00 |
| Expire Date | 2025-01-17 |
| Day's Range | 5.00 - 5.12 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 751 |
Business WireDexcom G7 Now Connects Directly to Apple Watch in the U.S.
SAN DIEGO, June 05, 2024--DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that the Dexcom G7 Continuous Glucose Monitoring (CGM) System now connects directly to Apple Watch* in the United States. Dexcom G7 is the first and only CGM available with Direct to Apple Watch, offering users the freedom and convenience of real-time glucose readings on their wrist even when their iPhone isn’t with them.†
ZacksDexCom (DXCM) Declines on Potential Competition for Stelo (revised)
DexCom (DXCM) stock declined on Monday following the FDA approval of another over-the-counter glucose monitor, potentially fueling competition for Stelo.
Business WireDexcom Wins Access to Dexcom ONE for 100,000 People Living With Type 2 Diabetes
EDINBURGH, Scotland, June 04, 2024--DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring for people with diabetes, today announced a significant advancement in access to its products for those treating Type 2 diabetes (T2D) with basal insulin injections. The company, which pioneered CGM technology 25 years ago, has secured access to its Dexcom ONE sensor for around 100,000 T2D users in France. The reimbursement guidance offers people aged over two years who are
